Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As a Dr., you should appreciate how challenging making any inroads against CNS diseases is, esp Alzheimers. Even more challenging than treating cancer. Cancer discoveries have relied on precision medicine to match effective treatments w/receptive patients. CNS research is following oncology research's lead. Read recent publications by Hampel. One size does not fit all w/cancer and CNS diseases. It's not that easy.
You missed the point of that investigation and its conclusions. Precision medicine.
FYI Donepezil is a SR1 agonist.
Maybe he might want to be close to his new best friend and collaborator, Christopher Missling? Maybe Harald is shacking up at Chris' place in NYC until he gets himself settled? What do they have in common? Both are focused on Alzheimer's research and precision medicine, work for intl biotech companies focused on the CNS, prior working relationship, co-published and presented a scientific paper last year, both have multiple degrees from U of Munich, Munich native sons, speak german, both in their 50's, etc.
Anavex's goal: get the damn drug approved for anything, period. That's step 1, and given the abysmal track record of drugs in CNS clinical trials, I think Anavex needs to take EVERY advantage to increase the probabilities for success, and that includes using precision med to pre-screen. With that. Anavex increases the odds for efficacy and drug tolerance. I've seen no mention/proof anavex hasn't pre-screened for wild types.
Does it concern you only 10 and 20mg arms are included in the PDD trial?
I wouldn't get too excited. Only mouse data so far and we all know how translational that is to humans. If we went by mouse data, heck, 2-73 would be annointed the cure for all CNS diseases. How many severe genetic diseases have been cured by gene therapy to date?
Techically speaking, AVXL has been outperforming the small and mid cap biotechs, as represented by the XBI ETF, since January. Also, since then, the stock has been bullish.
Way overvalued. Clinical stage only, $42/share, and 1.127B market cap
Best case it gets approved in 10 years
Have you done research on Alzheimer's or Parkinson's in a professional capacity?
Odd that that site is the only mention of dosage strength. clinicaltrials.gov doesn't even list the dosages for this trial. 10mg and 20mg seem too low to me based on the AD trial results. Doesn't make sense to me.
Ph2 PDD trial dosages of 2-73. What are they for the high dose and medium dose arms? Someone posted a couple days ago that the dosages are 10mg and 20mg. I've never seen the dosages disclosed previously, so I'm wondering where they read or heard this information? Anyone know? I think they are probably mistaken.
$5.80 next week, or $5.96, for the bottom?
Initial results from which clinical study, the new Ph 2/3 or the old Ph 2a trial?
No, he's teamed up w/Merck according to the agenda insert-text-here
Huh, it only has one of the most promising neuro drugs in clinical trials and you reckon it should be valued as a penny stock? Don't think so. There's a reason this is the most trafficked stock mb on ihub 4 yrs running
$100M
AXSM ripe for a sell off. Price way above its 200MA. Classic micro cap biotech pump n dump.
Which trial? The unblinded Ph2a Alzheimers extension?
Two year old article from a rag website the best you can do? He assumed Anavex had to follow the Axovant playbook for how to run a developmental biotech company. That's laughable. Regardless, he actually was neutral towards investing in Anavex and didn't even give it a thumbs down
I specifically remember reading for either this 7 week trial, or the earlier planned 12 week trial, that caregivers are to record seizures in a diary for the month immediately before trial start to get baseline data before each patient starts taking 2-73. Patients enrolled in this 7 week trial are given the option of continuing on the drug for an additional 12 weeks. Would that include them in future 12 week trial? IDK.
Umm, why would you assume that? I remember reading that the caregivers are to record # of seizures in a diary as part of the trial. For the first month, the Rett patients aren't to be given the drug and the caregivers record # of seizures that month. That info will be used to compare against how many seizures they have while on 2-73. I'm sure Anavex wants recent data for each of the patients that are partaking in the trial.
They want to record how many seizures the trial's girls have for a month to then compare to how many they have while on the drug.
Well, not technically. I think baseline data is first gathered before drug administration, which takes some time (A couple weeks for AD and PD? A month for the Rett trial).
After patients are enrolled into each of the 3 trials, do they immediately begin the trial, or do patients not begin until ALL the patients have been enrolled? For the Ph 2a, they began as they were enrolled.
Anyone know what causes inflammation in Alzheimer's, biochemically speaking, and how does 2-73 reduce Alzheimer's driven inflammation biochemically? I know inflammation is caused by the immune system reacting to something.
What's up with NTRP today, was there some bad news released? Down 12%. Good buying opportunity if you want in.
NTRP gaps down to below $5 this week. Question is: has the next pump n dump begun in earnest?
I thought this little run on the heels of the Biogen failure might be the start of another NTRP P&D, but after doing my TA analysis, the stock is still in a downtrend. Odd, b/c most stocks, especially in the biotech sector, have either stabilized or have broken out to the upside.
An FDA approved drug that is actually decent and they go bankrupt? WTF? Was this the fault of management? WTF, went wrong with this company and who is to blame? I'd like more than just short quip for an answer.
I didnt ubderstand your point
Nowadays, women live longer than men, so doesn't it make sense they'd have more cases of Alzheimer's?